Genocea Biosciences Inc. (NASDAQ:GNCA) traded down 3.6% on Thursday . The stock traded as low as $4.05 and last traded at $4.07, with a volume of 152,690 shares trading hands. The stock had previously closed at $4.22.

Several equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a research report on Friday, April 1st. Finally, Stifel Nicolaus raised their price objective on shares of Genocea Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, April 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Genocea Biosciences presently has an average rating of “Buy” and an average price target of $18.13.

The company has a 50 day moving average of $4.15 and a 200 day moving average of $4.27. The firm’s market capitalization is $114.58 million.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. On average, equities analysts expect that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.